This question has likely been covered before, and apologies if so but,
Has anyone crunched the numbers and come to a potential Market Cap/Share price if:
- Daybue sales continue as projected.
- NNZ-2591 is successful in the 4 indications being trialed.
- The target market for those 4 indications truly is 5x larger than Rett syndrome.
- NEU reaches an agreement similar to what we did with ACADIA (including upfront and milestone payments etc).
- No TO is accepted, NEU partners with either ACADIA or someone similar.
If we essentially do with NNZ-2591 what we've done with Trofinetide, what kind of number(s) do we end up with??
I'm sure ive seen a few valuation models from various learned posters here, but can anyone refresh our memory? Have models changed in light of today's success?
Many thanks in advance.
What a brilliant day for the NEU team, we investors, but most importantly, the families living with these conditions.
Share Price, page-8407
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.09 |
Change
0.390(3.07%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.12 | $12.89 | $7.055M | 542.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24882 | $14.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.43 | 7361 | 5 |
View Market Depth
| Last trade - 15.59pm 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |